{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:33:23Z","timestamp":1791318803575,"version":"4.3.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1002\/jps.23417","type":"journal-article","created":{"date-parts":[[2013,1,4]],"date-time":"2013-01-04T15:32:47Z","timestamp":1357313567000},"page":"1036-1053","source":"Crossref","is-referenced-by-count":53,"title":["Pharmaceutical Nanotechnology Nanoparticle-Based Topical Ophthalmic Formulations for Sustained Celecoxib Release"],"prefix":"10.1016","volume":"102","author":[{"given":"Mohammed Mostafa","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abd-Elgawad Helmy","family":"Abd-Elgawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama Abd-Elazeem","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M.","family":"Jablonski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.23417_bb0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000068563","article-title":"Topical non-steroidal anti-inflammatory therapy in ophthalmology","volume":"217","author":"Schalnus","year":"2003","journal-title":"Ophthalmologica"},{"key":"10.1002\/jps.23417_bb0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2337\/db05-1621","article-title":"Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology","volume":"56","author":"Kern","year":"2007","journal-title":"Diabetes"},{"key":"10.1002\/jps.23417_bb0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/IAE.0b013e3181884fa6","article-title":"Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients","volume":"29","author":"Maloney","year":"2009","journal-title":"Retina"},{"key":"10.1002\/jps.23417_bb0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3129\/can j ophthalmol.06-109","article-title":"Immuno-histochemical expression of COX-2 and c-kit in metastatic uveal melanoma","volume":"42","author":"Frota","year":"2007","journal-title":"Can J Ophthalmol"},{"key":"10.1002\/jps.23417_bb0025","first-page":"6","article-title":"The discovery and function of COX-2","volume":"49","author":"Needleman","year":"1997","journal-title":"J Rheumatol Suppl"},{"key":"10.1002\/jps.23417_bb0030","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.survophthal.2009.07.005","article-title":"Nonsteroidal antiinflammatory drugs in ophthalmology","volume":"55","author":"Kim","year":"2010","journal-title":"Surv Ophthalmol"},{"key":"10.1002\/jps.23417_bb0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1076\/ceyr.18.2.79.5386","article-title":"Increased va-sodilatory prostaglandin production in the diabetic rat retinal vasculature","volume":"18","author":"Johnson","year":"1999","journal-title":"Curr Eye Res"},{"key":"10.1002\/jps.23417_bb0040","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/bjo.2004.064915","article-title":"Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma","volume":"89","author":"Tong","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1002\/jps.23417_bb0045","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ajo.2005.01.030","article-title":"Celecoxib, a selective inhibitor of cyclooxygenase 2 for therapy of diffuse anterior scleritis","volume":"139","author":"Bauer","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1002\/jps.23417_bb0050","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1023\/B:PHAM.0000045231.51924.e8","article-title":"Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration","volume":"21","author":"Ayalasomayajula","year":"2004","journal-title":"Pharm Res"},{"key":"10.1002\/jps.23417_bb0055","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1167\/iovs.05-0531","article-title":"Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage","volume":"47","author":"Amrite","year":"2006","journal-title":"Invest Ophth Vis Sci"},{"key":"10.1002\/jps.23417_bb0060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2005.02.019","article-title":"Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model","volume":"511","author":"Ayalasomayajula","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1002\/jps.23417_bb0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1167\/iovs.07-0214","article-title":"Effect of eye pigmentation on transscleral drug delivery","volume":"49","author":"Cheruvu","year":"2008","journal-title":"Invest Ophth Vis Sci"},{"key":"10.1002\/jps.23417_bb0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1350-9462(97)00002-5","article-title":"Ophthalmic drug delivery systems: Recent advances","volume":"17","author":"Le Bourlais","year":"1998","journal-title":"Prog Retinal Eye Res"},{"key":"10.1002\/jps.23417_bb0075","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0002-9394(81)90177-X","article-title":"Idoxuridine-liposome therapy for herpes simplex keratitis","volume":"91","author":"Smolin","year":"1981","journal-title":"Am J Ophthalmol"},{"key":"10.1002\/jps.23417_bb0080","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.2042-7158.1991.tb03534.x","article-title":"Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles","volume":"43","author":"Losa","year":"1991","journal-title":"J Pharm Pharmacol"},{"key":"10.1002\/jps.23417_bb0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1023\/A:1018977130559","article-title":"Design of new formulations for topical ocular administration: Polymeric nanocapsules containing metipranolol","volume":"10","author":"Losa","year":"1993","journal-title":"Pharm Res"},{"key":"10.1002\/jps.23417_bb0090","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.progpolymsci.2007.05.017","article-title":"Biodegradable polymers as biomaterials","volume":"32","author":"Nair","year":"2007","journal-title":"Prog Polym Sci"},{"key":"10.1002\/jps.23417_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"Kumari","year":"2010","journal-title":"Colloids Surfaces B: Bioenterfaces"},{"key":"10.1002\/jps.23417_bb0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0168-3659(93)90097-O","article-title":"Preparation of biodegradable nanospheres of water soluble and insoluble drugs with D, L-lactide\/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior","volume":"25","author":"Niwa","year":"1993","journal-title":"J Control Release"},{"key":"10.1002\/jps.23417_bb0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijpharm.2006.01.029","article-title":"Study of an alginate\/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin","volume":"315","author":"Liu","year":"2006","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.23417_bb0110","series-title":"Basic statistics for the health sciences","author":"Kuzma","year":"2005"},{"key":"10.1002\/jps.23417_bb0115","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/jbm.a.30395","article-title":"Synthesis, characterization, and in vitro 5-fu release behavior of poly(2,2- dimethyltrimethylene carbonate)-poly(ethylene glycol)- poly(2,2-dimethyltrimethylene carbonate) nanoparticles","volume":"76","author":"Zhang","year":"2006","journal-title":"J Biomed Mater Res A"},{"key":"10.1002\/jps.23417_bb0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijpharm.2004.11.027","article-title":"PLGA nanoparticles containing praziquantel: Effect of formulation variables on size distribution","volume":"290","author":"Mainardes","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.23417_bb0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2007.01.016","article-title":"Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo","volume":"119","author":"Mittal","year":"2007","journal-title":"J Control Release"},{"key":"10.1002\/jps.23417_bb0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0168-3659(02)00127-X","article-title":"Residual polyvinyl alcohol associated with poly (D, L-lactide-co- glycolide) nanoparticles affects their physical properties and cellular uptake","volume":"82","author":"Sahoo","year":"2002","journal-title":"J Control Release"},{"key":"10.1002\/jps.23417_bb0135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijpharm.2006.10.036","article-title":"Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres","volume":"334","author":"Mao","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.23417_bb0140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0168-3659(00)00367-9","article-title":"Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterization and in vivo evaluation","volume":"70","author":"Redhead","year":"2001","journal-title":"J Control Release"},{"key":"10.1002\/jps.23417_bb0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0168-3659(98)00138-2","article-title":"Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS","volume":"59","author":"Scholes","year":"1999","journal-title":"J Control Release"},{"key":"10.1002\/jps.23417_bb0150","first-page":"1621","article-title":"Preparation and evaluation of quercetin loaded lecithin-chitosan nanoparticles for topical delivery","volume":"6","author":"Tan","year":"2011","journal-title":"Int J Nanomed"},{"key":"10.1002\/jps.23417_bb0155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-5173(02)00461-1","article-title":"Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A","volume":"249","author":"El-Shabouri","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.23417_bb0160","first-page":"2116","article-title":"PLGA nanoparticles of anti-tubercular drug: Drug loading and release studies of a water in-soluble drug","volume":"2","author":"Tripathi","year":"2010","journal-title":"Int J Pharm Tech Res"},{"key":"10.1002\/jps.23417_bb0165","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1208\/s12249-010-9519-4","article-title":"Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles","volume":"11","author":"Yadav","year":"2010","journal-title":"AAPS Pharm Sci Tech"},{"key":"10.1002\/jps.23417_bb0170","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1248\/cpb.59.1117","article-title":"Short- and long-term stability of lyophilised melatonin- loaded lecithin\/chitosan nanoparticles","volume":"59","author":"Hafner","year":"2011","journal-title":"Chem Pharm Bull"},{"key":"10.1002\/jps.23417_bb0175","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1016\/j.biomaterials.2010.01.042","article-title":"Enteric-coated capsules filled with freeze-dried chitosan\/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery","volume":"31","author":"Sonaje","year":"2010","journal-title":"Biomaterials"},{"key":"10.1002\/jps.23417_bb0180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/(SICI)1098-2299(199606)38:2<116::AID-DDR6>3.0.CO;2-M","article-title":"Freeze-drying of itraconazole-loaded nanosphere suspensions: A feasibility study","volume":"38","author":"De Chasteigner","year":"1996","journal-title":"Drug Dev Res"},{"key":"10.1002\/jps.23417_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(90)90024-X","article-title":"Design of nanoparticles of less than 50nm diameter: Preparation, characterization and drug loading","volume":"62","author":"Seijo","year":"1990","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.23417_bb0190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0168-3659(93)90103-C","article-title":"The preparation of sub-200nm poly(lactide-co- glycolide) microspheres for site-specific drug delivery","volume":"25","author":"Scholes","year":"1993","journal-title":"J Control Release"},{"key":"10.1002\/jps.23417_bb0195","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.2147\/IJN.S19497","article-title":"Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells","volume":"6","author":"Kim","year":"2011","journal-title":"Int J Nanomed"},{"key":"10.1002\/jps.23417_bb0200","unstructured":"USP29-NF24, \u201cThe United States Pharmacopeia\u201d, 29th, 2005. Pharmaceutical dosage forms, ophthalmic preparation and uniformity of dosage units chapters, United States Phar- macopeial Convention, Inc. Maryland (online version) http:\/\/ www.pharmacopeia.cn\/."},{"key":"10.1002\/jps.23417_bb0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijpharm.2011.03.007","article-title":"Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery","volume":"410","author":"Wu","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.23417_bb0210","first-page":"1329","article-title":"viscous corneal protection by sodium hyaluronate, chondroitin sulfate, and methylcellulose","volume":"25","author":"Hammer","year":"1984","journal-title":"Invest Ophth Vis Sci"},{"key":"10.1002\/jps.23417_bb0215","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0168-3659(00)00329-1","article-title":"Carbopol\/pluronic phase change solutions for ophthalmic drug delivery","volume":"69","author":"Lin","year":"2000","journal-title":"J Control Release"},{"key":"10.1002\/jps.23417_bb0220","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0378-5173(99)00060-5","article-title":"A method using biodegradable polylactides\/polyethylene glycol for drug release with reduced initial burst","volume":"182","author":"Huang","year":"1999","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.23417_bb0225","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijpharm.2004.12.030","article-title":"New surface modified lipid nanoparticles as delivery vehicles for salmon calcitonin","volume":"296","author":"Garcia-Fuentes","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.23417_bb0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijpharm.2007.06.011","article-title":"Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles","volume":"346","author":"Budhian","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.23417_bb0235","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0168-3659(95)00164-6","article-title":"Biodegradable nanoparticles-from sustained release formulations to improved site specific drug delivery","volume":"39","author":"Leroux","year":"1996","journal-title":"J Control Release"},{"key":"10.1002\/jps.23417_bb0240","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijpharm.2007.04.013","article-title":"Gels and liposomes in optimized ocular drug delivery: Studies on ciprofloxacin formulations","volume":"343","author":"Budai","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.23417_bb0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4103\/0250-474X.42985","article-title":"Formulation and evaluation of Pentoxifylline-loaded poly(e-caprolactone) microspheres","volume":"70","author":"Tamizharasi","year":"2008","journal-title":"Ind J Pharm Sci"},{"key":"10.1002\/jps.23417_bb0250","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0378-5173(83)90064-9","article-title":"Mechanism of solute release from porous hydrophilic polymers","volume":"15","author":"Korsmeyer","year":"1983","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.23417_bb0255","first-page":"217","article-title":"Kinetic modeling on drug release from controlled drug delivery systems","volume":"67","author":"Dash","year":"2010","journal-title":"Acta Pol Pharm Drug Res"},{"key":"10.1002\/jps.23417_bb0260","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/eye.1999.17","article-title":"Reliability of drop size from multi-dose eye drop bottles: Is it cause for concern?","volume":"13","author":"German","year":"1999","journal-title":"Eye (Lond)"},{"key":"10.1002\/jps.23417_bb0265","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0378-5173(02)00058-3","article-title":"Biocompatible stabilizers in the preparation of PLGA nanoparticles: A factorial design","volume":"238","author":"Vandervoort","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.23417_bb0270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0168-3659(03)00098-1","article-title":"Polymer relationships during preparation of chitosan-alginate and poly-L- lysine-alginate nanospheres","volume":"89","author":"De","year":"2003","journal-title":"J Control Release"},{"key":"10.1002\/jps.23417_bb0275","first-page":"68","article-title":"Nanomedicines for overcoming biological barriers","volume":"58","author":"Alonso","year":"2004","journal-title":"Biomed Pharmacoth"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915311667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915311667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T23:29:02Z","timestamp":1562542142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915311667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0022354915311667"],"URL":"https:\/\/doi.org\/10.1002\/jps.23417","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}